Literature DB >> 33172925

Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.

Guo-Fu Li1,2, Xiao-Xiao An2,3, Yichao Yu4, Li-Rong Jiao2,3, Daniele Canarutto5, Guo Yu6,2, Guangji Wang7, Dan-Na Wu8, Yin Xiao9.   

Abstract

Entities:  

Keywords:  acid secretion; gastric acid; gastroesophageal reflux disease

Year:  2020        PMID： 33172925     DOI： 10.1136/gutjnl-2020-323366

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

Review 1.  Gastroduodenal injury and repair: novel targets for therapeutic intervention.

Authors:  Susan J Hagen
Journal:  Curr Opin Gastroenterol       Date:  2022-11-01       Impact factor: 2.741

2.  Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19.

Authors:  Dan-Na Wu; Li-Rong Jiao; Guo-Fu Li; Guo Yu
Journal:  Eur J Clin Pharmacol       Date:  2022-05-16       Impact factor: 3.064

3.  Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.

Authors:  Simone Bastrup Israelsen; Martin Thomsen Ernst; Andreas Lundh; Lene Fogt Lundbo; Håkon Sandholdt; Jesper Hallas; Thomas Benfield
Journal:  Clin Gastroenterol Hepatol       Date:  2021-05-11       Impact factor: 13.576

4.  An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.

Authors:  Jan Homolak; Ivan Kodvanj; Vladimir Trkulja
Journal:  Clin Drug Investig       Date:  2021-02-19       Impact factor: 2.859

5.  Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis.

Authors:  Maddalena Zippi; Sirio Fiorino; Roberta Budriesi; Matteo Micucci; Ivan Corazza; Roberta Pica; Dario de Biase; Claudio Giuseppe Gallo; Wandong Hong
Journal:  World J Clin Cases       Date:  2021-04-26       Impact factor: 1.337

6.  Factors associated to potentially inappropriate prescribing in older patients according to STOPP/START criteria: MoPIM multicentre cohort study.

Authors:  Marisa Baré; Marina Lleal; Sara Ortonobes; Maria Queralt Gorgas; Daniel Sevilla-Sánchez; Nuria Carballo; Elisabet De Jaime; Susana Herranz
Journal:  BMC Geriatr       Date:  2022-01-11       Impact factor: 3.921

7.  Inflammation at the crossroads of Helicobacter pylori and COVID-19.

Authors:  Ileana Gonzalez; Cristian Lindner; Ivan Schneider; Miguel A Morales; Armando Rojas
Journal:  Future Microbiol       Date:  2021-12-17       Impact factor: 3.165

8.  The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study.

Authors:  Asher Shafrir; Ariel A Benson; Lior H Katz; Tiberiu Hershcovici; Menachem Bitan; Ora Paltiel; Ronit Calderon-Margalit; Rifaat Safadi; Michal Shauly-Aharonov
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

9.  H2 antagonists, proton pump inhibitors and COVID-19.

Authors:  Kazuyoshi Hirota
Journal:  J Anesth       Date:  2022-01-24       Impact factor: 2.931

Review 10.  The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs.

Authors:  Hao Shen; Nu Zhang; Yuqing Liu; Xuerong Yang; Yuanyuan He; Qi Li; Xiaoyan Shen; Yulian Zhu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.